#1 Clinical Trials Search in Europe

Clostridia, Cluster Xiva, Strain Relative Clostridium_Q Symbiosum, Live

This article examines two clinical trials investigating the use of live bacterial strains for treating different intestinal conditions. The first trial focuses on preventing recurrent Clostridioides difficile infection using a drug called VE303, while the second trial evaluates VE202 for treating mild to moderate ulcerative colitis. Both drugs contain multiple strains of live bacteria and are being studied to assess their safety and efficacy in managing these gastrointestinal disorders.

Table of Contents

What is CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE CLOSTRIDIUM_Q SYMBIOSUM, LIVE?

CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE CLOSTRIDIUM_Q SYMBIOSUM, LIVE is a type of bacteria that is being studied as a potential treatment for certain gut-related conditions. It is part of a larger group of bacterial strains that make up two investigational drugs called VE303 and VE202[1][2]. These drugs are known as live biotherapeutic products (LBPs), which means they contain live organisms (in this case, bacteria) that are used to prevent, treat, or cure a disease or condition.

What conditions does it treat?

Based on the ongoing clinical trials, this bacterial strain, as part of the VE303 and VE202 formulations, is being studied to treat two main conditions:

  1. Clostridioides difficile infection (CDI): This is a serious intestinal infection that can cause severe diarrhea and potentially life-threatening complications. VE303 is being studied to prevent recurrent CDI[1].
  2. Ulcerative colitis (UC): This is a type of inflammatory bowel disease that causes inflammation and ulcers in the digestive tract. VE202 is being studied to treat mild-to-moderate ulcerative colitis[2].

How does it work?

While the exact mechanism of action is still being studied, these bacterial strains are believed to work by helping to restore a healthy balance of bacteria in the gut. In conditions like CDI and UC, the normal balance of gut bacteria (also known as the microbiome) is disrupted. By introducing beneficial bacteria, these treatments aim to:

  • Compete with harmful bacteria for resources
  • Produce substances that inhibit the growth of harmful bacteria
  • Help regulate the immune system in the gut
  • Improve the overall health of the intestinal lining

Current clinical trials

Two major clinical trials are currently underway to study the effectiveness of these bacterial strains:

1. VE303 for Clostridioides difficile infection (CDI)

This is a Phase 3 clinical trial called the RestoratiVE303 Study[1]. Key points include:

  • It’s studying VE303 for preventing recurrent CDI in patients who have recently been treated for a CDI episode.
  • The study is randomized, double-blind, and placebo-controlled, which means participants are randomly assigned to receive either VE303 or a placebo, and neither the participants nor the researchers know who is receiving which treatment.
  • The main goal is to compare the CDI recurrence rate at 8 weeks between those treated with VE303 and those given a placebo.
  • The study is also looking at safety, quality of life, and how well the bacterial strains colonize the gut.

2. VE202 for Ulcerative Colitis (UC)

This is a Phase 2 clinical trial studying VE202 in patients with mild-to-moderate ulcerative colitis[2]. Key points include:

  • It’s also a randomized, double-blind, placebo-controlled study.
  • The main goal is to evaluate how well VE202 improves the appearance of the intestinal lining (endoscopic response) after 8 weeks of treatment.
  • The study is also assessing the safety of VE202.

How is it administered?

Both VE303 and VE202 are administered orally in the form of capsules[1][2]. This makes them relatively easy for patients to take at home. The exact dosing schedule may vary depending on the specific study and condition being treated.

Potential side effects

As these treatments are still in clinical trials, the full range of potential side effects is not yet known. However, the studies are carefully monitoring for any adverse events. Common side effects of probiotics and similar treatments may include:

  • Mild digestive symptoms like gas or bloating
  • Changes in bowel movements

It’s important to note that one of the main goals of these clinical trials is to assess the safety of these treatments[1][2].

Conclusion

CLOSTRIDIA, CLUSTER XIVA, STRAIN RELATIVE CLOSTRIDIUM_Q SYMBIOSUM, LIVE, as part of the VE303 and VE202 formulations, represents a promising new approach to treating gut-related conditions like Clostridioides difficile infection and ulcerative colitis. By harnessing the power of beneficial bacteria, these treatments aim to restore balance to the gut microbiome and improve patient outcomes. While the results of the ongoing clinical trials are eagerly awaited, this research highlights the growing importance of understanding and manipulating the gut microbiome in treating various diseases.

Aspect VE303 Trial (CDI) VE202 Trial (Ulcerative Colitis)
Condition Recurrent Clostridioides difficile infection Mild to moderate ulcerative colitis
Drug VE303 (multiple live bacterial strains) VE202 (multiple live bacterial strains)
Administration Oral capsules Oral capsules
Treatment Duration 14 days 8 weeks
Primary Objectives Compare CDI recurrence rates, assess safety Evaluate endoscopic response, monitor adverse events
Study Design Randomized, double-blind, placebo-controlled Randomized, double-blind, placebo-controlled
Follow-up Period 24 weeks Not specified in provided data

FAQ

  • What conditions are being studied in these clinical trials? The clinical trials are studying two different intestinal conditions: recurrent Clostridioides difficile infection (CDI) and mild to moderate ulcerative colitis.
  • What are the main drugs being tested in these trials? The main drugs being tested are VE303 for recurrent CDI and VE202 for ulcerative colitis. Both drugs contain multiple strains of live bacteria.
  • How are the drugs administered in these trials? Both VE303 and VE202 are administered orally as capsules.
  • What are the primary goals of these clinical trials? The primary goals are to evaluate the safety and efficacy of the drugs. For VE303, the main objective is to compare CDI recurrence rates between the drug and placebo. For VE202, the main goals are to assess endoscopic response and monitor for adverse events.
  • How long do the treatment periods last in these trials? In the VE303 trial for CDI, the treatment period lasts 14 days. In the VE202 trial for ulcerative colitis, the treatment period is 8 weeks.

Ongoing Clinical Trials on Clostridia, Cluster Xiva, Strain Relative Clostridium_Q Symbiosum, Live

  • Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +8

  • Study on VE202 for Patients with Mild-to-Moderate Ulcerative Colitis

    Not recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Hungary Lithuania The Netherlands Poland

Glossary

  • Clostridioides difficile infection (CDI): An infection of the large intestine caused by the bacterium Clostridioides difficile, often resulting in diarrhea and other gastrointestinal symptoms.
  • Ulcerative colitis: A chronic inflammatory bowel disease that causes inflammation and ulcers in the lining of the large intestine and rectum.
  • Recurrent CDI: The reoccurrence of Clostridioides difficile infection after initial treatment, often within weeks or months of the first episode.
  • Endoscopic response: An improvement in the appearance of the intestinal lining as observed through an endoscope, which is a tool used to visually examine the inside of the body.
  • Placebo: An inactive substance that looks like the drug being tested but contains no active ingredients, used as a control in clinical trials.
  • Live bacterial strains: Living microorganisms that are used as therapeutic agents, often to help restore balance to the gut microbiome.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease that occurs during a clinical trial, whether or not it is related to the treatment being studied.
  • Standard of Care (SoC): The treatment that is accepted by medical experts as the most appropriate and widely used for a specific condition.
  • Randomized: A method used in clinical trials where participants are randomly assigned to different treatment groups to reduce bias.
  • Double-blind: A study design where neither the participants nor the researchers know which treatment is being given to which participant until after the trial is completed.

References

  1. http://clinicaltrials.eu/trial/study-on-ve303-for-preventing-recurrent-c-difficile-infection-in-patients/
  2. http://clinicaltrials.eu/trial/study-on-ve202-for-patients-with-mild-to-moderate-ulcerative-colitis/